前往化源商城

Cancer Biotherapy and Radiopharmaceuticals 2014-09-01

Subtelomeric demethylation deregulated hTERT expression, telomerase activity, and telomere length in four nasopharyngeal carcinoma cell lines.

Zi-Xiong Zhang, Yan Wang, Ze-Zhang Tao, Shi-Ming Chen, Bo-Kui Xiao, Tao Zhou

文献索引:Cancer Biother. Radiopharm. 29(7) , 289-94, (2014)

全文:HTML全文

摘要

Global DNA hypomethylation, in particular that of the gene promoter sequence in gene hypermethylation, is a well-known characteristic of human cancer. Subtelomeres are enriched CpG islands; methylation is believed to be a potential epigenetic regulator. However, regulation on the telomere length remains largely unknown. To demonstrate this correlation, four nasopharyngeal carcinoma cell lines (CNE, CNE1, CNE2, 5-8F) were treated for 72 hours with 0, 1, or 2.5 μM of the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC). Subtelomeric (D4Z4) level methylation was evaluated with a bisulfite assay, the human telomerase catalytic subunit (hTERT) expression was assayed by reverse transcription-polymerase chain reaction, the telomerase activity was detected using a telomeric repeat amplification protocol assay, and the telomere length was measured by Southern blot terminal restriction fragment analysis. There was significant demethylation following 5-aza-dC treatment, and a strongly repressed hTERT expression decreased the telomerase activity and remarkably shortened telomeres. Thus, partial subtelomeric methylation does not repress hTERT expression; conversely, demethylation may downregulate hTERT expression and shorten telomeres.

相关化合物

结构式 名称/CAS号 全部文献
溴化乙啶 结构式 溴化乙啶
CAS:1239-45-8
亚硫酸氢钠 结构式 亚硫酸氢钠
CAS:7631-90-5